Perspective Therapeutics, Inc. (CATX)

Market Cap	187.89M
Revenue (ttm)	1.56M
Net Income (ttm)	-63.79M
Shares Out	67.59M
EPS (ttm)	-1.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	599,773
Open	2.920
Previous Close	2.840
Day's Range	2.760 - 2.945
52-Week Range	2.700 - 19.100
Beta	1.23
Analysts	Strong Buy
Price Target	17.25 (+520.5%)
Earnings Date	Mar 4, 2025

About CATX

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-α-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as L...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1983
• Employees: 119
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: CATX

Financial Performance

In 2023, Perspective Therapeutics's revenue was $1.43 million, a decrease of -73.52% compared to the previous year's $5.42 million. Losses were -$46.51 million, 332.2% more than in 2022.

Analyst Forecast

According to 9 analysts, the average rating for CATX stock is "Strong Buy." The 12-month stock price forecast is $17.25, which is an increase of 520.50% from the latest price.

Price Target

$17.25

(520.50% upside)

Analyst Consensus: Strong Buy